Henderson Global Investors

Simba Sleep is a London-based company that specializes in designing and manufacturing mattresses, pillows, duvets, bedding, and bed bases. Founded in 2015, the company combines innovative materials such as precision-engineered foam and patented conical pocket springs to create a range of mattresses that promote comfortable sleep. Simba Sleep emphasizes the importance of quality rest in daily life, aiming to help customers improve their sleep experience. Its products are available for purchase online and in select retail locations, including John Lewis stores in the United Kingdom. Additionally, Simba Sleep offers financing options for customers looking to invest in better sleep.

Simba Sleep is a London-based company that specializes in designing and manufacturing mattresses, pillows, duvets, bedding, and bed bases. Founded in 2015, the company combines innovative materials such as precision-engineered foam and patented conical pocket springs to create a range of mattresses that promote comfortable sleep. Simba Sleep emphasizes the importance of quality rest in daily life, aiming to help customers improve their sleep experience. Its products are available for purchase online and in select retail locations, including John Lewis stores in the United Kingdom. Additionally, Simba Sleep offers financing options for customers looking to invest in better sleep.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Gartmore Investment Limited is a privately owned investment management firm based in London, United Kingdom. Established in 1969, the company specializes in managing hedge funds and offers a diverse array of investment products and services designed to cater to the needs of both retail and institutional clients. Gartmore operates as a subsidiary of Henderson Global Investors Limited and has a reputation for being a respected independent fund manager, focusing solely on asset management. The firm is dedicated to providing tailored investment solutions to meet the varying demands of its clientele.

New Star Asset Management is an investment management holding company. The company through its subsidiaries provides services in areas including UK investment funds, investment trusts, offshore funds/SICAVs, alternative investments, and Specialist institutional funds.

Sharda Cropchem Ltd is an Indian agrochemical company that specializes in the distribution of formulations and generic active ingredients for agricultural use. Its primary offerings include insecticides, herbicides, fungicides, and biocides, which contribute significantly to its revenue. The company operates through two main segments: Agrochemicals and Non-Agrochemicals. In addition to agrochemical products, Sharda Cropchem also provides a range of non-agricultural items, including conveyor belts, V-belts, timing belts, dyes, and general chemicals. The company markets its products primarily in Europe, with additional revenue generated from NAFTA countries, Latin America, and India. Through its subsidiaries, Sharda Cropchem aims to meet diverse industrial needs while maintaining a strong presence in the agrochemical sector.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

Homann Feinkost GmbH, established in 1876 and headquartered in Dissen, Germany, specializes in the production of chilled food products. The company offers a diverse range of items, including bread and dip, mayonnaise, salad dressings, and seafood salads. As of April 2015, it operates as a subsidiary of Gastronomia y Negocios S.A. Homann Feinkost aims to provide convenient and flavorful options suitable for various occasions, such as grilling, snacking, or enhancing meals.

Italian fitness and wellness chain